Format

Send to

Choose Destination
Ann Clin Transl Neurol. 2014 Jul;1(7):512-8. doi: 10.1002/acn3.76. Epub 2014 Jun 24.

Overcoming obstacles to repurposing for neurodegenerative disease.

Author information

1
Alzheimer's Drug Discovery Foundation 57 West 57th Street, Suite 904, New York City, New York, 10019.
2
Eip pharma, LLC 11 Channing Street, Cambridge, Massachusetts, 02183.
3
Faster Cures 1101 New York Ave, NW Suite 620, Washington, District of Columbia, 20005.
4
Sunnybrook Health Sciences Centre, University of Toronto Room A421- 2075, Bayview Avenue, Toronto, Ontario, M4N 3M5.
5
Cleveland Clinic 888 W Bonneville Ave, Las Vegas, Nevada, 89106.
6
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai One Gustave L Levy Pl, New York City, New York, 10029.
7
AstraZeneca 35 Gatehouse Drive, Waltham, Massachusetts, 02451.
8
SDG, LLC One Mifflin Place, Suite 400, Cambridge, Massachusetts, 02138.
9
FaegreBD Consulting 1050 K Street NW, Suite 400, Washington, District of Columbia, 20001.
10
Northwestern University Feinberg School of Medicine 710 North Lake shore Drive, Chicago, Illinois, 60611.
11
The Access Group 400 Connell Drive FL2, Berkeley Heights, New Jersey, 07922.
12
The Michael J. Fox Foundation for Parkinson's Research Grand Central Station, P.O. Box 4777, New York City, New York, 10163-4777.

Abstract

Repurposing Food and Drug Administration (FDA)-approved drugs for a new indication may offer an accelerated pathway for new treatments to patients but is also fraught with significant commercial, regulatory, and reimbursement challenges. The Alzheimer's Drug Discovery Foundation (ADDF) and the Michael J. Fox Foundation for Parkinson's Research (MJFF) convened an advisory panel in October 2013 to understand stakeholder perspectives related to repurposing FDA-approved drugs for neurodegenerative diseases. Here, we present opportunities on how philanthropy, industry, and government can begin to address these challenges, promote policy changes, and develop targeted funding strategies to accelerate the potential of FDA-approved repurposed drugs.

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center